Drug Trial Radar · NCT05845450
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
197
Planned (sponsor's estimate)
Start
May 11, 2023
Primary completion
May 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Gruppo Oncologico del Nord-OvestAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a window-of-opportunity umbrella platform trial enrolling non-metastatic resectable colorectal patients selected for the presence of a specific targetable molecular alteration. The study aims to test the activity of specific targeted agents/combinations given as a short-course pre-operative strategy, matched with the specific alteration detected, followed by standard of care surgery.
Conditions
- Colorectal Cancer
- Resectable Colorectal Carcinoma
Interventions
Trastuzumab deruxtecanDrug
trastuzumab deruxtecan 5.4 mg/kg IV on day 1
DurvalumabDrug
durvalumab 1500 mg IV on day 1
PanitumumabDrug
panitumumab 6 mg/kg IV on days 1 and 15
BotensilimabDrug
botensilimab 1 mg/kg on day 1
BalstilimabDrug
balstilimab 3 mg/Kg on days 1 and 15
SotorasibDrug
sotorasib 960 mg orally once daily from day 1 to 28
VorbipiprantDrug
vorbipiprant 90 mg orally bid from day 1 to 28
NivolumabDrug
240 mg IV on days 1 and 15
AmivantamabDrug
amivantamab at the dose of 1600 mg (2240 mg if body weight ≥ 80 Kg), subcutaneously, on days 1, 8, 15 and 22
BotensilimabDrug
Botensilimab at the dose of 75 mg, IV on day 1
BalstilimabDrug
balstilimab at the dose of 240 mg, IV on days 1, 15, 29 and 43
Primary outcomes
What the sponsor says the trial is designed to measure.
- major pathological response rateTime frame: 5 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, Lombardia/MI, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.